Myelin protein 0 peptide 106Y125Yinduced murine experimental autoimmune neuritis (EAN) is a CD4-positive T cellYmediated monophasic axonal inflammatory neuropathy; interferon-F is the key proinflammatory mediator. Experimental autoimmune neuritis is well suited for elucidating pathogenetic mechanisms underlying human acute axonal Guillain-Barré syndrome. Here, the functional role of the costimulatory molecule CD40 was defined by characterization of EAN in CD40-deficient mice. In contrast to immunized C57BL/6 mice, CD40-deficient mice were resistant to EAN owing to impaired priming of CD4-positive T-effector cells. To determine whether CD40 is a suitable candidate for the treatment of EAN, we administered monoclonal anti-CD40 antibody either before immunization or upon onset of neurologic signs. Prophylactic anti-CD40 treatment completely abolished CD4-positive T-cell priming. Therapeutic application of anti-CD40 prevented full activation of CD4-positive T cells that were in the process of priming and suppressed production of interferon-F in peripheral lymph nodes, spleen, and serum, and of interleukin-6, interleukin-12p40, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1, which are associated with activation of the nuclear factor-JB signaling pathway. This resulted in enhanced recovery by early generation of CD25-positive, Foxp3-positive, CD4-positive regulatory T cells. Thus, these experiments highlight the crucial role of CD40 as an important costimulatory molecule in EAN and suggest that it has potential as a therapeutic target in human neuritis.
INTRODUCTION
Autoimmune-mediated inflammation of the peripheral nervous system (PNS) is a disabling disorder that affects the motor, sensory, and autonomic systems. Up to 25% of patients require assisted ventilation because of respiratory muscle paresis, which contributes to unfavorable prognosis (1) . Disturbances of the autonomic nervous system, such as cardiac arrhythmia, hypertonia, hypotonia, ileus, or urinary retention, may be life-threatening (2) and may lead to permanent neurologic impairment.
Experimental autoimmune neuritis (EAN) in rodents induced either by immunization with myelin proteins or peptides or by transfer of autoreactive T cells (3Y7) shares clinical, electrophysiologic, and neuropathologic features with human autoimmune disorders of the PNS, particularly with regard to the underlying pathogenesis in which interferon-F (IFN-F)Y secreting CD4-positive T cells are the crucial effector cells (8Y10). Therefore, this model is ideally suited for identifying the underlying immunopathogenetic mechanisms by which both cellular and humoral immune responses are critically involved (11Y13). The immunologic network of components that may be involved has not yet been fully elucidated. In particular, the role of costimulatory molecules required for T-cell priming in EAN has not been the focus of functional studies.
CD40, a 50-kDa member of the tumor necrosis factor receptor family (14) , is expressed on hematopoietic cells that act as antigen-presenting cells, including B cells (14) , dendritic cells (15) , and macrophages (16) , as well as on CD8 T cells (17Y19). In addition, nonhematopoietic cells, such as endothelial cells and fibroblasts, are CD40-positive (20Y24). CD40 functions as a costimulatory molecule in cellular and humoral immune responses. CD40 is an important costimulatory molecule for T-cell priming via interaction with its ligand, CD40L (CD154) (14, 25, 26) , which is expressed on activated, antigenspecific, CD4-positive T-helper cells (27) and macrophages (21) in the vascular endothelium and on smooth muscle cells (21) . In rat myelin protein 0 (P0) peptide 180Y199Yinduced EAN, CD40 has been identified on mononuclear cells in the sciatic nerve by immunohistochemistry (28) , but the functional relevance of CD40 in EAN is still unknown.
In the present study, we have characterized P0 106Y125 Y induced EAN in CD40-deficient (CD40 0/0 ) mice and wild-type (WT; CD40 +/+ ) C57BL/6 mice to delineate its functional impact on this EAN model. Having shown that CD40 0/0 mice are resistant to P0 106Y125 Yinduced EAN, we next addressed the open and clinically relevant question on whether this observation can be used for a therapeutic approach, either prophylactically or therapeutically, in fully established EAN. Therefore, we antagonized CD40-mediated effects by treatment of the mice with a rat anti-mouse antibody either before immunization or on Day 9 postimmunizationVwhen neurologic signs are overt. Both approaches were highly protective either by rendering mice resistant to EAN or by ameliorating clinical EAN. Thus, these experiments highlight the crucial role of CD40 as an important costimulatory molecule in EAN, potentially of therapeutic relevance.
MATERIALS AND METHODS

Induction of Autoimmune Neuritis
C57B6.129P2-Cd40
tm1Kik /J (CD40 0/0 ) mice (Jackson Laboratories, Bar Harbor, ME) and C57BL/6J mice were bred in the specific pathogen-free animal facility of the University of Cologne. C57B6.129P2-Cd40 tm1Kik /J (CD40 0/0 ) mice were backcrossed for 9 generations to ensure a genetic background that was identical to that of WT control C57BL/6J (CD40 +/+ ) mice. Experiments were carried out according to local governmental regulations. Six-to 8-week-old male CD40 0/0 and CD40 +/+ mice were immunized as previously described (10) . In brief, 200 mg of P0 106Y125 (amino acid sequence
Medisch Centrum, Leiden, The Netherlands) dissolved in dimethylsulfoxide (Sigma, Taufkirchen, Germany) and 0.5 Kg of Mycobacterium tuberculosis strain H 37 RA (Difco, Detroit, MI) emulsified in 25 KL of PBS and 25 KL of Freund incomplete adjuvant (Difco) were applied subcutaneously into hind foot pads on Day 0 and subcutaneously into the back on Day 7 postimmunization; 500 ng of pertussis toxin (Sigma) per mouse was injected intraperitoneally on Days 0 and 2 postimmunization. Control mice were treated with PBS.
Anti-CD40 Monoclonal Antibody Treatment
To antagonize CD40, we treated CD40 +/+ mice with 100 Kg of monoclonal rat anti-mouse CD40 antibody (clone 1C10; BioLegend, Fell, Germany) intraperitoneally every second day starting on Day j5 postimmunization (i.e. group anti-CD40 dj5 ) or on Day 9 postimmunization (i.e. group anti-CD40 d9 ). Control mice received 100 Kg of rat IgG 2a intraperitoneally in addition to P0 106Y125 .
Assessment of Clinical Scores
On Days 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 22, 24, 26, 28, 30, 32, 34, 35, 36, 38, 40, 42 , and 43 postimmunization, mice were clinically examined in blinded fashion to determine disease activity according to a clinical scoring system defined as follows: 0, normal; 1, ruffled fur; 2, floppy tail, weak grip, and slightly reduced motility; 3, mild paraparesis with impaired motility; 4, severe paraparesis with significantly reduced motility; 5, tetraparesis with complete immobilization; 6, death.
Flow Cytometry
On Days 9, 15, 22, 35, and 43 postimmunization, mice were intracardially perfused with 0.9% NaCl in deep CO 2 anesthesia. Peripheral lymph nodes (PLNs) and splenic leukocytes were isolated and analyzed after triple immunofluorescence staining followed by flow cytometry, as described previously (10) . All antibodies, except for F4/80 (Serotec, Düsseldorf, Germany), were purchased from BD Biosciences (Heidelberg, Germany) (Table) . Intracellular staining for interleukin (IL)-17a, IFN-F, and IL-10 and nuclear staining for Foxp3 were performed after magnetic cell separation of CD4-positive T cells using the CD4-positive T-cell isolation kit (Miltenyi, Bergisch Gladbach, Germany), according to the manufacturer's instructions. Afterward, CD4-positive T cells were stimulated in cell culture for 3 days in the presence of plate-bound anti-CD3 antibody, soluble anti-CD28 antibody, recombinant mouse IL-1A antibody, mouse IL-6 antibody, and transforming growth factor-A protein (all from BD Biosciences) in complete RPMI-1640 tissue culture medium (Sigma). Thereafter, cells were restimulated with phorbol myristate acetate and ionomycin (both from Sigma) in the presence of Monensin (BD Golgistop protein transport inhibitor; BD Biosciences), harvested, washed, and stained. Flow cytometry was performed on a BD FACSCalibur (BD Biosciences) with CellQuest Pro software (BD Biosciences) and on a BD FACSVerse (BD Biosciences) with FACSuite software (BD Biosciences).
IFN-F and IL-6 Enzyme-Linked Immunospot Assay
The frequencies of IFN-FY and IL-6Yproducing P0 106Y125 Y specific lymphocytes in PLNs and spleen were determined using IFN-FY and IL-6Yspecific enzyme-linked immunospot assays, respectively, on Days 9, 15, 22, and 35 postimmunization, as described previously (10) . 
Histopathology and Immunohistochemistry
For histopathology and immunohistochemistry, animals were intracardially perfused with 0.9% NaCl in deep CO 2 anesthesia on Days 9, 15, 22, 35, and 43 postimmunization. Spinal cord, sciatic nerve, and gastrocnemius muscle were investigated by conventional histopathology, immunohistochemistry, and immunofluorescence, as described previously (10) . In brief, 1 sciatic nerve per animal was excised from the lumbar spinal cord to the periphery (including parts of the gastrocnemius muscle), mounted on a thick filter paper with Tissue Tek OCT compound (Miles Scientific, Naperville, IL), snap-frozen in isopentane (Fluka, Neu-Ulm, Germany) that had been precooled on dry ice, and stored at j80-C until the preparation of serial 10-Km frozen sections for immunohistochemistry. In addition to previously described protocols, polyclonal rabbit anti-mouse CD40 and rabbit anti-mouse CD40L (both from Antibodies-Online, Atlanta, GA) were used to determine CD40-positive and The other sciatic nerve and the corresponding gastrocnemius muscle were postfixed in 3.9% phosphate-buffered glutaraldehyde (Merck, Darmstadt, Germany) for 48 hours, osmicated, and embedded in epoxy resin (Serva, Heidelberg, Germany) for preparation of 1-Km semithin sections.
RNA Extraction and Reverse Transcription
RNA was extracted from the cryopreserved PLNs and spleen of 2 animals per group on Days 9, 15, 22, and 35 postimmunization using the TRIzol/chloroform method (Invitrogen, Karlsruhe, Germany), according to the manufacturer's instructions. RNA concentrations were measured by fluorometry. First-strand complementary DNA (cDNA) was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany).
Quantitative Reverse TranscriptionYPolymerase Chain Reaction
Transcription of messenger RNA (mRNA) was analyzed by quantitative reverse transcriptionYpolymerase chain reaction using TaqMan gene expression assays for IFN-F, CD40, and IL-12p40 (Applied Biosystems). Water, instead of cDNA, was used as negative control. Polymerase chain reactions were prepared with the cDNA equivalent of 5 ng of RNA in a final volume of 20 KL. All samples were studied in triplicate. For normalization, the murine genes of TATA-box binding protein and RNA polymerase II were chosen as reference genes (29) . Normalized data were calibrated by comparison to expression values for untreated C57BL/6 mice using the $$C t method (30) .
Statistical Analysis
To test for differences in clinical disease activity between the experimental groups, we applied a 2-tailed MannWhitney U test. The numbers of inflammatory cells in the sciatic nerve were determined by counting immunoreactive cells in high-power fields (microscopic magnification: 400Â) of sections stained with CD4-, CD8-, CD19-, or F4/80-specific monoclonal antibodies, respectively, in samples of at least 4 animals per experimental group on Days 9, 15, 22, and 35 postimmunization. Data are presented as mean T SD. Statistical significance of the differences in the $$C t values of mRNA transcripts and antigen-specific T cells in PLNs and spleen and the numbers of inflammatory infiltrates in the sciatic nerve were determined using a 2-tailed Mann-Whitney U test. A value of p G 0.05 was considered significant. All experiments were performed at least 2 times with 4 animals per experimental 0/0 mouse (E) and an anti-CD40 dj5 mouse (F), corresponding to resident resting macrophages, as evidenced by their lack of iNOS expression (insets to E and F). In the sciatic nerve of an anti-CD40 d9 mouse, the number of endoneurial macrophages is slightly increased (G). However, they are not activated, as demonstrated by their absent iNOS expression (inset to G). There are numerous activated macrophages in the sciatic nerve of a P0 106Y125 Yimmunized CD40 +/+ mouse that express iNOS (H and inset therein). (IYL) Semithin sections of the sciatic nerve of a P0 106Y125 Yimmunized CD40 0/0 mouse (I) and an anti-CD40 dj5 mouse (J) exhibit a normal distribution of large and small fibers without acute axonal damage. Single axons in the sciatic nerve of an anti-CD40 d9 mouse are damaged (K). There is pronounced axonal damage in a P0 106Y125 Yimmunized CD40 +/+ mouse, with acute axonal damage (arrow), loss of nerve fibers (asterisk), and inflammatory infiltrates (arrowhead) (L). (MYP) Lack of >-APP expression in the sciatic nerve of a P0 106Y125 Yimmunized CD40 0/0 mouse (M), an anti-CD40 dj5 mouse (N), and an anti-CD40 d9 mouse (O), respectively, indicates normal axonal transport. Note the numerous >-APPYexpressing axons in the sciatic nerve of a P0 106Y125 Yimmunized CD40 +/+ mouse (P) indicating disturbed axonal transport. Immunohistochemistry with anti-CD4 (AYD), antiYF4/80 (EYH), anti-iNOS (inset to EYH), and >-APP (MYP); slight counterstaining with hemalum; semithin section with toluidine blue staining (IYL). In CD40 0/0 mice, severe paraparesis corresponding to a clinical score of 4 in CD40 +/+ mice, described previously (10, 31, 32), was totally abolished. During the study, only 40% of CD40 0/0 mice developed ruffled fur, whereas neurologic signs were absent (Figs. 1A, B) . In prophylactically treated anti-CD40 dj5 mice, the course of disease was similar to that in CD40 0/0 mice (Figs. 1A, B) . Absence of EAN in both CD40 0/0 mice and anti-CD40 dj5 mice was reflected by the lack of CD4-positive T cells, CD8-positive T cells, and CD19-positive B cells in the sciatic nerve, which harbored only a few resident iNOS-positive macrophages remaining in their resting state during the study (Figs. 2, 3) . Accordingly, axonal damage, disturbed axonal transport (Fig. 2) , and neurogenic muscular atrophy (Fig. 4) were absent in CD40 0/0 mice and anti-CD40 dj5 mice. Up to Day 10 postimmunization, therapeutically treated anti-CD40 d9 mice exhibited disease courses comparable to those in CD40 +/+ mice (Figs. 1A, B) . However, within 3 days, anti-CD40 treatment prevented worsening of disease (Figs. 1A, B) , with only few CD4-positive T cells having infiltrated the sciatic nerve on Day 15 postimmunization (Figs. 2, 3A , p G 0.005), whereas endoneurial CD8-positive T cells and CD19-positive B cells were not detectable (Figs. 3B, C) . On Day 15 postimmunization, a few macrophages had homed to the sciatic nerves; their numbers decreased within 7 days thereafter (Figs. 2, 3D) . In contrast to CD40 +/+ mice, iNOS expression on endoneurial macrophages was not increased in anti-CD40 d9 mice, thereby preventing axonal damage (Fig. 2) , disturbed axonal transport (Fig. 2) , and, consequently, neurogenic muscular atrophy (Fig. 4) .
Absence of Neuritis Is Attributable to Low IFN-F Production
During the study, in P0 106Y125 Yimmunized CD40 0/0 mice and anti-CD40 dj5 mice, IFN-F mRNA and protein levels were consistently low in PLNs and spleen (Figs. 5A, B) On Day 9 postimmunization, IFN-F mRNA and protein levels in the PLNs and spleen of anti-CD40 d9 mice were comparable to those in P0 106Y125 Yimmunized CD40 +/+ mice, declining rapidly thereafter in the PLNs and serum but persisting unchanged in the spleen (Fig. 5A, Thus, in anti-CD40 dj5 mice, IFN-F production was as low as in P0 106Y125 Yimmunized CD40 0/0 mice, rendering them unable to develop neuritis; in P0 106Y125 Yimmunized CD40 +/+ mice, high IFN-F levels contributed to neuritis. Therefore, comparable to anti-CD40 d9 mice on Day 9 postimmunization, after the beginning of anti-CD40 treatment, IFN-F levels in anti-CD40 d9 mice rapidly declined, thus correlating with disease activity.
Impaired T-Cell Priming in P0 106Y125
YImmunized CD40 0/0 Mice and P0 106Y125 YImmunized Anti-CD40 dj5 Mice Both P0 106Y125 Yimmunized CD40 0/0 mice and anti-CD40 dj5 mice failed to activate T cells, as evidenced by low numbers of the T-cell activation markers CD28, CD69, and CD44 on splenic lymphocytes on Day 15 postimmunization. Expression of these molecules was comparable to that of splenic CD3-positive T cells in nonimmunized CD40 +/+ control mice, thus contrasting with numerous activated CD3-positive T cells in P0 106Y125 Yimmunized CD40 +/+ mice (Fig. 6 ). On Day 15 postimmunization, the numbers of activated CD28-positive, CD69-positive, and CD44-positive splenic T cells in anti-CD40 d9 mice were only slightly increased versus P0 106Y125 Yimmunized CD40 0/0 mice and anti-CD40 dj5 mice, respectively, thus contrasting with P0 106Y125 Yimmunized CD40 +/+ mice (Fig. 6 ).
Absence of CD40 and Anti-CD40 Treatments Impairs CD40L Expression in the Sciatic Nerve of P0 106Y125 YImmunized Mice
In nonimmunized CD40 0/0 mice, CD40L was expressed on the vascular endothelium and fibroblasts of the sciatic nerve and, as expected, CD40 was absent in the sciatic nerve (Fig. 7) . In nonimmunized CD40 +/+ mice, CD40 and CD40L were expressed by vascular endothelial cells and fibroblasts of the sciatic nerve (Fig. 7) . In addition, CD40 was expressed on macrophages. During the study, neither CD40-positive nor CD40L-positive cells homed to the sciatic nerve of P0 106Y125 Yimmunized CD40 0/0 mice or anti-CD40 dj5 mice. CD40L expression was confined to the vascular endothelium (Fig. 7) . This was in striking contrast to P0 106Y125 Yimmunized CD40 +/+ mice, in which single CD40-positive and CD40L-positive cells were present in the sciatic nerve on Day 9 postimmunization, increasing up to Day 15 postimmunization when some CD40-positive cells and numerous CD40L-positive cells had homed to the sciatic nerve (Fig. 7) ; a few CD40L-positive cells even persisted up to Day 43 postimmunization (data not shown). On Day 9 postimmunization, the number of CD40-positive and CD40L-positive cells in the sciatic nerve of anti-CD40 d9 mice was comparable to that of P0 106Y125 Yimmunized CD40 +/+ mice. However, on Day 15 postimmunization, CD40-positive and CD40L-positive cells had already vanished from the sciatic nerve of anti-CD40 d9 mice (Fig. 7) .
Absence of CD40 and Anti-CD40 Treatments Reduces Intercellular Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, IL-6, and IL-12p40 After P0 106Y125 Immunization On Day 15 postimmunization, the sciatic nerve of P0 106Y 125 Yimmunized CD40 0/0 mice and anti-CD40 dj5 mice harbored significantly decreased numbers of intercellular adhesion molecule-1 (ICAM-1)Yexpressing and vascular cell adhesion molecule-1 (VCAM-1)Yexpressing blood vessels, in contrast to P0 106Y125 Yimmunized CD40 +/+ mice (Fig. 8A , p G 0.005; Fig. 8B , p G 0.01). In addition, IL-6Yproducing splenic cells (Fig. 8C , p G 0.01) and IL-12p40 mRNA in the spleen (Fig. 8D , p G 0.005) were significantly decreased versus P0 106Y125 Yimmunized CD40 +/+ mice. In anti-CD40 d9 mice, the numbers of ICAM1Yexpressing and VCAM-1Yexpressing blood vessels in the sciatic nerve were significantly decreased versus P0 106Y 125 Yimmunized CD40 +/+ mice (Fig. 8A , p G 0.005; Fig. 8B , p G 0.01) and slightly increased versus P0 106Y125 Yimmunized CD40 0/0 and anti-CD40 dj5 mice. Splenic IL-6Yproducing cells and IL-12p40 mRNA in the spleen were also significantly decreased versus P0 106Y125 Yimmunized CD40 +/+ mice (Fig. 8C,  p G 0.01; Fig. 8D , p G 0.005) and slightly increased compared with P0 106Y125 Yimmunized CD40 0/0 and anti-CD40 dj5 mice. The expression of ICAM-1 and VCAM-1, the number of IL6Yproducing splenic cells, and IL-12p40 mRNA levels were similarly low in nonimmunized CD40 +/+ and CD40 0/0 mice (data not shown).
Thus, in P0 106Y125 Yimmunized CD40 0/0 , anti-CD40 dj5 , and anti-CD40 d9 mice, mediators associated with the activation of the nuclear factor-JB (NF-JB) signaling pathway (i.e. ICAM-1, VCAM-1, IL-6, and IL-12p40) were significantly decreased versus those in P0 106Y125 Yimmunized CD40 (Fig. 9) . In P0 106Y125 Yimmunized CD40 0/0 mice, the numbers of CD25-positive, Foxp3-negative, CD4-positive T cells remained low during the study (Fig. 9) . In anti-CD40 dj5 mice, the numbers of splenic CD25-positive, Foxp3-negative, CD4-positive T cells slightly increased, but this increase did not differ significantly from that in P0 106Y 125 Yimmunized CD40 0/0 mice. In P0 106Y125 Yimmunized CD40 +/+ mice, the numbers of splenic CD25-positive, Foxp3-negative, (Fig. 9) . In anti-CD40 d9 mice, splenic CD25-positive, Foxp3-positive, CD4-positive regulatory T cells increased rapidly, reached their maximum on Day 15 postimmunization (Fig. 9 , p G 0.001 vs P0 106Y125 Yimmunized CD40 +/+ mice), and slowly declined thereafter up to Day 35 postimmunization (Fig. 9) .
DISCUSSION
The aim of the present study was to define whether the costimulatory molecule CD40 contributes to the pathogenesis of P0 106Y125 Yinduced murine EAN. Interestingly, CD40 0/0 mice were completely resistant to P0 106Y125 immunization. The resistance of P0 106Y125 Yimmunized CD40 0/0 mice to EAN could be attributed to an impairment of CD4-positive T-cell priming in the peripheral lymphatic organs, evidenced by low numbers of activated T cells compared with P0 106Y 125 Yimmunized CD40 +/+ mice. Consequently, they failed to produce IFN-F, the major proinflammatory mediator in P0 106Y 125 Yinduced EAN (10, 31, 32) , at levels sufficient to cause neuritis. A major effect of IFN-F is the stimulation of macrophages to produce iNOS. In vitro and in various infectious diseases (e.g. murine cerebral and systemic toxoplasmosis) (33Y37), low IFN-F levels do not allow activation of macrophages, thereby avoiding further IFN-F production by activated T cells. In addition, the activation status of macrophages correlates with the target-oriented cytotoxic effect on pathogen agents, as demonstrated in vitro with Leishmania major amastigotes (38, 39) . Functionally important, lack of CD4 and CD8 T-cell activation rendered these cells unable to home to the sciatic nerve, their target organ. Accordingly, CD40L-positive T cells were absent in the sciatic nerves of P0 106Y125 Yimmunized CD40 0/0 mice, in contrast to P0 106Y125 Y immunized CD40 +/+ mice. Our data on the essential role of CD40 in CD4-positive T-cell priming in autoimmune-mediated inflammation of the PNS extend data on infectious disorders, as the requirement for CD40-mediated interaction for CD4-positive T-cell priming is not confined to autoimmune disorders of the PNS but is also reported in M. tuberculosis infection (40) .
Our experiments raise the clinically relevant question of whether these data can be used as a promising concept in EAN therapy, either prophylactically or therapeutically (anti-CD40 dj5 /anti-CD40 d9 ). Indeed, prophylactic anti-CD40 therapy was sufficient to inhibit activation of T cells, rendering mice resistant to EAN, similarly to CD40 0/0 mice. Regarding CD40 neutralization as a therapeutic tool, anti-CD40 treatment was effective when started with the onset of clinical disease. Thus, progression of EAN was prevented, and recovery was enhanced. This was attributed to the prevention of complete and enduring T-cell activation, as indicated by reduced numbers of CD28-positive T cells. Because CD28 is the first and very important costimulatory molecule in the cascade of T-cell activation (41) , its absence prevents further T-cell activation. In addition, the loss of CD40 on the vascular endothelium in the sciatic nerve rendered the few CD40L-positive T cells unable to home to the sciatic nerve. A similar mechanism was observed in vitro by reduction of CD40 surface expression via small interfering RNA, thereby preventing the induction of endothelial cell adhesion molecule expression and lymphocyte adhesion (42) . In the present study, reduced ICAM-1 and VCAM-1 expression on the vascular endothelium of the sciatic nerve further impaired homing of P0 106Y125 Yspecific T cells to the sciatic nerve. In vitro studies in a porcine xenograft transplantation model revealed that the interaction between human CD40L-positive T cells and CD40-positive porcine endothelial cells activated the NF-JB signaling pathway (43) . Linkage of CD40/CD40L and the NF-JB signaling pathway is also supported by experiments in a murine model of arterial injury induced by carotid ligation; this procedure significantly decreased recruitment of macrophages to the injured artery in CD40 0/0 mice, which was attributed to impaired NF-JB activation with marked down-regulation of NF-JBYrelated genes, including ICAM-1, VCAM-1, and IL-6 (44). In this regard, our results of decreased IL-6 and IL-12p40 mRNA and protein levels, together with reduced ICAM-1 and VCAM-1 expression, indicate that the NF-JB signaling pathway was less activated in murine EAN in the absence of CD40.
In anti-CD40 d9 mice, low numbers of P0 106Y125 Yspecific CD4-positive T cells were accompanied by high numbers of splenic CD25-positive, Foxp3-positive, CD4-positive regulatory T cells that are likely to have accelerated recovery from EAN. An increase in regulatory T cells after CD40 blockade was also identified as an important mechanism for reducing the accumulation of antigen-specific CD4-positive T cells and for recruiting CD25-positive, Foxp3-positive, CD4-positive regulatory T cells to the graft in a murine model of skin transplantation (45) . A similar mechanism was described in murine myelin oligodendrocyte glycoproteinYinduced experimental autoimmune encephalitis in which CD4-positive T cells from mice with experimental autoimmune encephalitis were cocultured with microglial cells in the presence of CD40L. High CD40 expression induced by high-dose IFN-F/myelin oligodendrocyte glycoproteinYstimulated microglia and subsequent CD40/CD40L interaction were important in generating CD25-positive, Foxp3-negative, CD4-positive effector T cells, but not CD25-positive, Foxp3-positive, CD4-positive regulatory T cells. By contrast, low-dose IFN-F/myelin oligodendrocyte glycoproteinYstimulated microglia with low CD40 expression induced predominantly CD25-positive, Foxp3-positive, CD4-positive regulatory T cells (46) .
In conclusion, these experiments highlight the functional importance of CD40-mediated immune reactions in murine EAN and suggest that specific anti-CD40 therapy is a promising concept in the treatment of autoimmune neuritis because it is effective in both prophylactic and therapeutic paradigms.
